GlassScriptPhysician profile
Julie Seibert
NPI 1740253822
$12,212.00
in general payments reported to CMS, 2019-2025
62 companies · $47.57 in 2025
The $47.57 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,560 · 2020: $1,009 · 2021: $2,376 · 2022: $3,523 · 2023: $3,150 · 2024: $547 · 2025: $47.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,311.85 | 2020-2025 | Ubrelvy, Qulipta, Duopa |
| Ucb, INC. | $1,303.06 | 2019-2024 | Briviact, Nayzilam, Fintepla |
| Emd Serono, INC. | $739.72 | 2019-2024 | Mavenclad |
| Biogen, INC. | $675.38 | 2019-2023 | Tysabri, Vumerity |
| Mdd US Operations, LLC | $457.11 | 2019-2024 | Gocovri, Gocovri, Apokyn |
| Amgen INC. | $444.44 | 2019-2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $433.42 | 2019-2024 | Rytary, Lyvispah |
| Lundbeck LLC | $431.76 | 2019-2024 | Vyepti, Rexulti |
| Genzyme Corporation | $400.80 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $384.32 | 2019-2023 | Ingrezza, Ongentys |
| Lilly USA, LLC | $346.64 | 2020-2024 | Amyvid, Reyvow, Emgality |
| Alexion Pharmaceuticals, INC. | $339.26 | 2019-2023 | Soliris |
| Sk Life Science, INC. | $321.98 | 2021-2024 | |
| Celgene Corporation | $321.08 | 2021-2023 | Zeposia |
| Sunovion Pharmaceuticals INC. | $293.86 | 2020-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Seibert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.